NCT03734692View on ClinicalTrials.gov

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

July 1, 2024

Study Completion Date

January 10, 2027

Conditions
Ovarian Cancer Recurrent
Interventions
DRUG

Rintatolimod

200 mg by IP administration over 1-2 hours

DRUG

Pembrolizumab

200 mg will be administered as a 30 minute IV infusion

DRUG

Cisplatin

50mg/m\^2 solution

Trial Locations (1)

15213

Magee-Womens Hospital of UPMC, Pittsburgh

Sponsors

Collaborators (1)

AIM ImmunoTech Inc.
All Listed Sponsors
collaborator

AIM ImmunoTech Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Robert Edwards

OTHER